This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Orlistat in simple obesity

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

743 patients with BMI 28-47 were recruited.

There was an initial placebo run-in period of 4 weeks during which a mildly hypocaloric diet was commenced.

Only patients (668) who completed this run-in and who had taken more than 75% of their tablets were enrolled into the 1 year single-blind trial of orlistat in combination with a hypocaloric diet.

In the second year patient were re-randomised to orlistat or placebo in combination with a eucaloric diet (one designed to maintain a stable weight).

Reference:

  • 1) Sjostrom, L, Rissanen, A, Andersen, T. et al (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352, 167-72.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.